Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

s the most widely used type of delivery-system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was launched in Europe and other international markets in October 2006 and is an investigational device in Japan where it is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... SEATTLE, Dec. 6 A challenge donation from ... the evening,s fundraising total to more than $7 million ... Hutch," a portion of the live auction during which ... brought in $6.4 million to be directed toward the ... to battle cancer. ,, The black-tie Gala took ...
(Date:12/4/2009)... Therapeutics, Inc. today announced that data from pre-clinical studies of ... in vitro and animal models of human chronic myeloid ... upcoming 51st Annual Meeting of the American Society of Hematology ... 2009. The poster will be presented by Stemline,s collaborators at ...
(Date:12/3/2009)... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... the treatment of cardiovascular and metabolic disease, today announced ... its Phase 2 FDG-PET clinical trial of VIA-2291. ... carried out at five sites in the US and ...
(Date:12/3/2009)... NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. ... Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke ... New Delhi, India, November 22, 2009. Beike is ... , The conference, organized ...
Breaking Biology Technology:34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3
... FSE: "HBP") has filed a Form 20-F Registration Statement with ... common shares with the SEC. , , ... SEC, allows certain foreign corporations to register securities with the ... of 1934, as amended. The Company,s Form 20-F is a ...
... MannKind Corporation,(Nasdaq: MNKD ), focused on discovering, developing ... will present at,the Piper Jaffray 20th Annual Health Care Conference ... New York Palace Hotel in New York City. , ... link to the live web cast of the,presentation in the ...
... MLSS), the recognized leader in advanced injection technologies, today announced that it will be ... Greater New York Dental Meeting in New York City. , , ... 3, 2008, WHERE: Exhibit #2706, ... Center, ...
Other Biology Technology:Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission 2Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission 3Milestone Scientific to Showcase STA(TM) System at the Greater New York Dental Meeting in New York City 2Milestone Scientific to Showcase STA(TM) System at the Greater New York Dental Meeting in New York City 3
(Date:12/4/2009)... Using a new mathematical model of heart cells, University ... critical enzyme, calmodulin kinase II (CaM kinase), disrupts the ... study, which also involved Columbia University, was published online ... . , "Recently, researchers have developed great interest ...
(Date:12/3/2009)... to learn new information and adapt to changes in our ... to lie in the minute junctions where nerve cells communicate, ... researchers. The study is published online this week in the ... Wen-Biao Gan, PhD, associate professor of physiology and neuroscience at ...
(Date:12/3/2009)... in its 32nd year, the CTRC-AACR San Antonio Breast ... cancer science and world leaders from industry and academia ... This year, more than 8,500 scientists and other professionals ... in San Antonio from Dec. 9-13, 2009. The symposium ...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2Lifelong memories linked to stable nerve connections 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2New Healthcare Overpayment Recoupment Embezzlement Recovery Service Announced In Wake Of Launch of New Federal Task Force To Combat Healthcare Fraud C 61680 1New Healthcare Overpayment Recoupment Embezzlement Recovery Service Announced In Wake Of Launch of New Federal Task Force To Combat Healthcare Fraud C 61680 2New Healthcare Overpayment Recoupment Embezzlement Recovery Service Announced In Wake Of Launch of New Federal Task Force To Combat Healthcare Fraud C 61680 3New Healthcare Overpayment Recoupment Embezzlement Recovery Service Announced In Wake Of Launch of New Federal Task Force To Combat Healthcare Fraud C 61680 4Pelosi Statement on Senate Health Insurance Reform Bill 61677 1Opto electronic nose sniffs out toxic gases 14911 1Opto electronic nose sniffs out toxic gases 14911 2Opto electronic nose sniffs out toxic gases 14911 3
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
... GenomeLab GeXP Genetic Analysis System provides high-throughput, ... PCR*. The systems patented priming strategy ... PCR analysis to just a few genes ... more genes per reaction and more samples ...
... Shift Assay provides a convenient method to probe ... of MDR1 substrates. Thus, the kit may be ... molecules act as transport substrates for MDR1. Because ... of MDR1 substrates, the MDR1 Shift Assay can ...
... The Chemicon Detergent-OUT Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... The Med column is suitable for ...
Biology Products: